A
Axelyf
United States · Biotech
Axelyf develops RNA medicines for cancer and autoimmune diseases using its lipid nanoparticle delivery platform.
Platform
Its AXL lipid nanoparticle platform delivers RNA payloads into cells. The company uses its ANNA AI model to guide lipid design.
Programs
Its development pipeline includes AX-004, an in vivo CAR-T program targeting solid tumors, and AX-003 for autoimmune hepatitis. These are development programs rather than marketed treatments.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity offering with founder debt conversions | Undisclosed | Participants not disclosed |